Technologies search results
7 Results for ''
-
SPEAR: Ultrasensitive Protein Detection in Small Samples
Spear Bio uses a DNA nanotechnology-driven approach developed at the Wyss Institute that allows the sensitive detection of protein biomarkers in small samples using standard instruments to create new research and diagnostic assays. An ultra-sensitive assay detecting neutralizing antibodies against SARS-CoV-2 will be the first to be commercialized. -
Molecular Nucleic Acid Detection Technology to Empower Patients with Self-Testing Capabilities
This technology provides an innovative molecular diagnostic assay for high-speed, sensitive, and specific detection of nucleic acids from SARS-CoV-2 or other pathogens, performed in a newly devised reusable base unit with pathogen-specific, one-time-use consumables – first prototyped at the Wyss Institute, then transformed into an inexpensive, reliable and manufacturable detection system by 3EO Health. -
Immunostimulatory RNA Therapeutic for Treatment of Infectious Disease and Cancer
Our novel dsRNAs stimulate the immune system to inhibit cancer, bacterial, and viral infections including SARS-CoV-2 and multiple influenza strains. -
OMNIVAX: Broadly Deployable Infection Vaccine Platform
OMNIVAX is an immuno-material-based vaccine platform technology able to create safe and effective therapeutic and prophylactic vaccines against viral and bacterial threats. Its modular approach enables the rapid creation of vaccines for pathogens using known and unknown antigens. Current approaches include vaccines against some viral diseases. -
FcMBL: Broad-Spectrum Pathogen Capture for Infectious Disease Diagnosis and Therapy
The Problem Infectious diseases have plagued humanity for millennia, and the pathogens that infect and sicken humans are constantly evolving. Severe infections can cause sepsis, a life-threatening condition in which a patient’s immune system overreacts to the infection. The body starts to attack itself, which can lead to tissue damage, organ failure, and death. Sepsis... -
INSPECTR™: Direct-to-Consumer Molecular Diagnostic
INSPECTR™ is a molecular diagnostic platform that combines freeze-dried synthetic gene networks with cell-free expression systems to create novel biosensors that detect and report the presence of a target DNA or RNA molecule without the need for power or lab equipment. This technology was licensed by Wyss startup Sherlock Biosciences in 2019. -
Human Organs-on-Chips
Organ Chips are microfluidic devices lined with living human cells for drug development, disease modeling, and personalized medicine. Launched in 2014, Wyss startup Emulate, Inc., is leveraging the Wyss Institute’s Organ Chip technology to mimic human organs in vitro, enabling faster, better, and cheaper drug development and insights into human health.